胰高血糖素样肽和二肽基肽酶⁃4抑制剂在炎症性肠病治疗中的研究进展

Progress of Research on Glucagon⁃like Peptide and Dipeptidyl Peptidase⁃4 Inhibitor in Treatment of Inflammatory Bowel Disease

炎症性肠病(IBD)是一种非特异性、易复发的慢性肠道炎症性疾病,主要包括溃疡性结肠炎(UC)和克罗恩病(CD),其病因和发病机制尚未完全阐明,但目前认为与环境、遗传、免疫反应异常等因素有关。目前IBD已成为全球范围内备受关注的疾病,根据流行病学资料显示,IBD发病率在我国呈逐年上升趋势。但迄今为止,尚无能够完全治愈该疾病的药物。最近,胰高血糖素样肽(GLP)及其降解酶抑制剂二肽基肽酶⁃4(DPP⁃4)抑制剂在IBD治疗中引起了广泛研究和关注。本文就GLP和DPP⁃4抑制剂在IBD治疗中的研究进展作一综述。

Inflammatory bowel disease(IBD)is a non-specific and easily recurrent chronic inflammatory disease of the intestine,mainly including ulcerative colitis(UC)and Crohn's disease(CD).Its etiology and pathogenesis have not been fully clarified,but it is currently thought to be related to factors such as environmental,genetic and immune response abnormalities.At present,IBD has become a globally concerning disease.According to epidemiological data,the incidence of IBD is increasing year by year in China.But so far,there is no drug that can completely cure the disease.Recently,glucagon-like peptide(GLP)and its degradation enzyme inhibitor dipeptidyl peptidase-4(DPP-4)inhibitor have attracted widespread research and attention in the treatment of IBD.This article reviewed the progress of research on GLP and DPP-4 inhibitor in the treatment of IBD.